CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
MOXIdevice
Likely dose
MOXI fractionated 1927nm laser, once monthly for three monthsAI-extracted
Key inclusion· 5
  • ✓Fitzpatrick Skin Phototype V and VI
  • ✓Age 18–75 years
  • ✓Clinically significant hyperpigmentation on face that patient desires treatment for
  • ✓Willing to withhold aesthetic therapies (except those prescribed by Investigator) for study duration
Key exclusion· 17
  • ✕Fitzpatrick Skin Phototypes I–IV
  • ✕Known allergies/irritant contact dermatitis to hydroquinone, retinol, zinc oxide, or topical anesthetics (benzocaine, tetracaine)
  • ✕Active local or systemic disorders affecting wound healing
  • ✕History of systemic granulomatous disease (e.g., sarcoidosis, tuberculosis) or connective tissue disorders (e.g., SLE, scleroderma)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05493280
NCT05493280N/ACompleted
CompareCT.gov

Quantifying Hyperpigmentation Response to Fractionated 1927nm in Fitzpatrick Skin Phototype V and VI: A Pilot Study

University of Texas Southwestern Medical Center·interventional·Posted Aug 9, 2022·Updated Dec 15, 2025

In Brief

A clinical study evaluating MOXI for Hyperpigmentation. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The primary objective of this study is to assess the efficacy of 1927nm non-ablative fractionated laser therapy to treat hyperpigmentation in patients ages 18-75 with Fitzpatrick Skin Phototypes V and VI and explore an effective, adjunctive pre- and post-procedural regimen to prevent iatrogenic dyspigmentation or scarring in this population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperpigmentation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedAug 9, 2022
Enrollment StartNov 14, 2022
Primary CompletionJul 26, 2024
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.9 years ago

Interventions

MOXIdevice

Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.